[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sukowati et al., 2018 - Google Patents

Serum stem cell growth factor beta for the prediction of therapy response in hepatocellular carcinoma

Sukowati et al., 2018

View PDF @Full View
Document ID
1550711096597154665
Author
Sukowati C
Patti R
Pascut D
Ladju R
Tarchi P
Zanotta N
Comar M
Tiribelli C
Crocè L
Publication year
Publication venue
BioMed Research International

External Links

Snippet

Introduction. Chronic inflammatory response is one of major contributors in the development of hepatocellular carcinoma (HCC). Inflammatory molecules, such as cytokines and growth factors in the circulation, can be useful in the diagnosis and prognosis of the patients. The …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology

Similar Documents

Publication Publication Date Title
Sukowati et al. Serum stem cell growth factor beta for the prediction of therapy response in hepatocellular carcinoma
Capone et al. Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead‐Based Immunoassays
Estevez et al. Differential serum cytokine profiles in patients with chronic hepatitis B, C, and hepatocellular carcinoma
Cao et al. The inflammatory CXC chemokines, GROαhigh, IP-10low, and MIGlow, in tumor microenvironment can be used as new indicators for non-small cell lung cancer progression
Shahini et al. Updating the clinical application of blood biomarkers and their algorithms in the diagnosis and surveillance of hepatocellular carcinoma: a critical review
Zhao et al. Database mining of genes of prognostic value for the prostate adenocarcinoma microenvironment using the cancer gene atlas
Carone et al. Immune gene expression profile in hepatocellular carcinoma and surrounding tissue predicts time to tumor recurrence
Zhang et al. C8B in complement and coagulation cascades signaling pathway is a predictor for survival in HBV-related hepatocellular carcinoma patients
Carr et al. C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors
Capone et al. Cytokinome profile evaluation in patients with hepatitis C virus infection
Wang et al. Serum cytokine profiles of melanoma patients and their association with tumor progression and metastasis
Zhang et al. A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients
Jin et al. Bioinformatics analysis of potential therapeutic targets and prognostic biomarkers amid CXC chemokines in ovarian carcinoma microenvironment
Gong et al. Prognostic value of neutrophil‐to‐lymphocyte ratio associated with prognosis in HBV‐infected patients
Cui et al. Identification of colorectal cancer-associated macrophage biomarkers by integrated bioinformatic analysis
Johansson et al. Plasma levels of growth‐related oncogene (CXCL 1‐3) associated with fibrosis and platelet counts in HCV‐infected patients
Huang et al. Role of NCF2 as a potential prognostic factor and immune infiltration indicator in hepatocellular carcinoma
Zhao et al. Expression of chemokine CXCL8/9/10/11/13 and its prognostic significance in head and neck cancer
Cariani et al. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis
Xu et al. Identification of a necroptosis-related gene signature as a novel prognostic biomarker of cholangiocarcinoma
Tong et al. CCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma
Cai et al. Increased serum levels of macrophage inflammatory protein-3α and cystatin A predict a poor prognosis of nasopharyngeal carcinoma
Zhang et al. Determination of potential therapeutic targets and prognostic markers of ovarian cancer by bioinformatics analysis
Fujiwara et al. Hepatocellular carcinoma risk stratification by genetic profiling in patients with cirrhosis
de Groen et al. Endogenous IFNλ in viral hepatitis patients